MANAGEMENT OF INHIBITORS IN HEMOPHILIA
Introduction: The improved understanding of Acute Myeloid Leukemia (AML) pathobiology has led to significant advances in treatment options. AML is a highly heterogeneous disease, with clinical, morphological, cytogenetic, and molecular variability, which is crucial for developing targeted therapies...
Saved in:
| Main Author: | Gaye Kalacı Katayıfçı |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploration of biomarkers for inhibitor development in persons with hemophilia A
by: Meng-Ni Fan, et al.
Published: (2025-05-01) -
Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
by: Nicholas B. Abt, et al.
Published: (2014-01-01) -
Management of Acquired Hemophilia A in Elderly Patients
by: Tomoya Yamaguchi, et al.
Published: (2018-01-01) -
Guidelines for management of hemophilia—why, what, and how?
by: Alok Srivastava, et al.
Published: (2025-05-01)